13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Frankfurt |
88,030 |
13.06.24 19:55:08 |
-1,970 |
-2,19% |
0,000 |
0,000 |
89,260 |
88,030 |
|
REGENERON PHARMAC.DL-,001 |
881535 |
Frankfurt |
956,000 |
13.06.24 14:35:44 |
+19,800 |
+2,11% |
0,000 |
0,000 |
947,200 |
956,000 |